EcoDrugPlus

Retinoic Acid Receptor Rxr-Beta-A-Like

Ensembl ID : ENSCGOG00000005542
Gene Symbol: LOC115021592
3 Cross references
211 Possible Orthologues:

Retinoic Acid Receptor Alpha

Ensembl ID : ENSCGOG00000021300
Gene Symbol: RARA
3 Cross references
331 Possible Orthologues:

Retinoic Acid Receptor Beta

Ensembl ID : ENSCGOG00000005596
Gene Symbol: RARB
3 Cross references
394 Possible Orthologues:

Retinoic Acid Receptor Beta-Like

Ensembl ID : ENSCGOG00000009042
Gene Symbol: LOC115021399
2 Cross references
380 Possible Orthologues:

Retinoic Acid Receptor Gamma

Ensembl ID : ENSCGOG00000003425
Gene Symbol: RARG
3 Cross references
383 Possible Orthologues:

Retinoic Acid Receptor Gamma-A-Like

Ensembl ID : ENSCGOG00000023461
Gene Symbol: LOC115007996
3 Cross references
367 Possible Orthologues:

Rho-Associated Protein Kinase 2-Like

Ensembl ID : ENSCGOG00000024519
Gene Symbol: LOC115003454
3 Cross references
214 Possible Orthologues:

Ribosomal Protein L10

Ensembl ID : ENSCGOG00000013893
Gene Symbol: RPL10
3 Cross references
408 Possible Orthologues:

Ribosomal Protein L10a

Ensembl ID : ENSCGOG00000023617
Gene Symbol: RPL10A
3 Cross references
380 Possible Orthologues:

Ribosomal Protein L11

Ensembl ID : ENSCGOG00000017530
Gene Symbol: RPL11
3 Cross references
288 Possible Orthologues:

Ribosomal Protein L12

Ensembl ID : ENSCGOG00000007669
Gene Symbol: RPL12
3 Cross references
489 Possible Orthologues:

Ribosomal Protein L13

Ensembl ID : ENSCGOG00000022056
Gene Symbol: RPL13
3 Cross references
273 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).